KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Current Assets (2016 - 2025)

Jazz Pharmaceuticals has reported Current Assets over the past 16 years, most recently at $4.2 billion for Q4 2025.

  • Quarterly Current Assets fell 10.0% to $4.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.2 billion through Dec 2025, down 10.0% year-over-year, with the annual reading at $4.2 billion for FY2025, 10.0% down from the prior year.
  • Current Assets was $4.2 billion for Q4 2025 at Jazz Pharmaceuticals, up from $3.8 billion in the prior quarter.
  • Over five years, Current Assets peaked at $4.6 billion in Q4 2024 and troughed at $2.5 billion in Q1 2022.
  • The 5-year median for Current Assets is $3.2 billion (2021), against an average of $3.3 billion.
  • Biggest five-year swings in Current Assets: surged 108.67% in 2021 and later dropped 21.03% in 2022.
  • Tracing JAZZ's Current Assets over 5 years: stood at $2.6 billion in 2021, then decreased by 0.2% to $2.6 billion in 2022, then soared by 31.82% to $3.4 billion in 2023, then soared by 34.74% to $4.6 billion in 2024, then decreased by 10.0% to $4.2 billion in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $4.2 billion, $3.8 billion, and $3.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.